AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 89_CD 11_CD Fixed_VBN asset_NN investments_NNS continued_VBD Share_NN of_IN joint_JJ venture_NN assets_NNS and_CC liabilities_NNS 2004_CD 2003_CD $_$ m_CD $_$ m_CD Gross_NNP assets_NNS 174_CD Gross_NNP liabilities_NNS 174_CD The_DT group_NN disposed_VBD of_IN its_PRP$ joint_JJ venture_NN Advanta_NNP BV_NNP on_IN 1_CD September_NNP 2004_CD ._.
The_DT profit_NN on_IN disposal_NN is_VBZ disclosed_VBN in_IN Note_NN 3_CD ._.
12_CD Stocks_NNS 2004_CD 2003_CD $_$ m_CD $_$ m_CD Raw_NNP materials_NNS and_CC consumables_NNS 646_CD 715_CD Stocks_NNS in_IN process_NN 970_CD 1,206_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 1,404_CD 1,101_CD 3,020_CD 3,022_CD 13_CD Debtors_NNS 2004_CD 2003_CD $_$ m_CD $_$ m_CD Amounts_NNS due_JJ within_IN one_CD year_NN Trade_NNP debtors_NNS 3,636_CD 3,260_CD Less_RBR :_: Amounts_NNS provided_VBN for_IN doubtful_JJ debts_NNS 46_CD 57_CD 3,590_CD 3,203_CD Deferred_VBN taxation_NN Note_NN 5_CD 623_CD 732_CD Other_JJ debtors_NNS 492_CD 508_CD Prepayments_NNS and_CC accrued_VBN income_NN 1,110_CD 1,093_CD 5,815_CD 5,536_CD Amounts_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN Deferred_VBN taxation_NN Note_NN 5_CD 159_CD 165_CD Other_JJ debtors_NNS 78_CD 32_CD Prepayments_NNS and_CC accrued_VBN income_NN 222 227 459 424_CD 6,274_CD 5,960_CD Figures_NNS include_VBP prepaid_VBN pension_NN costs_NNS Note_VBP 28_CD ._.
Provisions_NNS for_IN doubtful_JJ debts_NNS 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Balance_NN at_IN beginning_NN of_IN year_NN 57_CD 56_CD 42_CD Profit_NN and_CC loss_NN account_NN charge_NN 811_CD Amounts_NNS utilised_JJ and_CC other_JJ movements_NNS 11_CD 7_CD 3_CD Balance_NN at_IN end_NN of_IN year_NN 46_CD 57_CD 56_CD
